Literature DB >> 16990651

Malignant prolactinoma: case report and review of the literature.

Marleen Kars1, Ferdinand Roelfsema, Johannes A Romijn, Alberto M Pereira.   

Abstract

Pituitary carcinomas are extremely rare. In general, the initial clinical, biochemical, and histological characteristics are of minimal utility in distinguishing benign adenomas from pituitary carcinomas. We describe a 63-year-old woman with a macroprolactinoma, who presented with diplopia and blurred vision. This unusual initial presentation and the subsequent aggressive clinical course, with diffuse local and distant intramedullary metastases, prompted us in retrospect to make a detailed analysis of the therapeutic interventions and histology. In addition, we reviewed all available literature on published cases of malignant prolactinoma and detailed their epidemiological, clinical, and histopathological characteristics. In brief, it is postulated that pituitary carcinomas arise from the transformation of initially large, but benign, adenomas. Unusual and/or atypical clinical manifestations appear to occur more frequently. In vivo, the development of dopamine agonist resistance in invasive macroprolactinoma is indicative of malignancy and should prompt the clinician to perform a biopsy of the tumor. For pituitary tumors that exhibit high mitotic activity, increased Ki-67 and/or p53 immunoreactivity, it may be useful to denote these tumors as 'atypical' prolactinomas to raise the possibility of future malignant development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990651     DOI: 10.1530/eje.1.02268

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  18 in total

1.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

2.  Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Authors:  Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  An unusual association of neuroendocrine tumors in MEN 1A.

Authors:  Mariela Varsavsky; Rebeca Reyes-García; Guillermo Alonso García; Manuel Muñoz-Torres
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 4.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

5.  Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy.

Authors:  Abel Po-Hao Huang; Shih-Hung Yang; Chi-Cheng Yang; Meng-Fai Kuo; Mu Zon Wu; Yong-Kwang Tu
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

6.  Heregulin regulates prolactinoma gene expression.

Authors:  George Vlotides; Odelia Cooper; Yen-Hao Chen; Song-Guang Ren; Yona Greenman; Shlomo Melmed
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

7.  Unusual clinical presentations of giant prolactinomas.

Authors:  Simona Grozinsky-Glasberg; Ilan Shimon
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

Review 8.  Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.

Authors:  Agatha A van der Klaauw; Tina Kienitz; Christian J Strasburger; Johannes W A Smit; Johannes A Romijn
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%.

Authors:  Y Ogawa; H Ikeda; T Tominaga
Journal:  J Endocrinol Invest       Date:  2009-05-21       Impact factor: 4.256

Review 10.  In search of a prognostic classification of endocrine pituitary tumors.

Authors:  Jacqueline Trouillas
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.